NCEL NewcelX Ltd. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1783036 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-15.3%
TTM EPS YoY-11.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-134.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets36.7%
Debt / equity0.00x
Current ratio0.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.33x
Accruals ratio-89.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $1.13M | $992,000 | $1.61M | $8.98M | $5.92M |
| SG&A expense | $1.35M | $805,000 | $1.33M | $6.51M | $5.94M |
| Operating income | -$2.56M | -$2.07M | -$3.02M | -$15.48M | -$11.86M |
| Interest expense | — | $45,054 | $119,920 | $95,211 | $48,100 |
| Pretax income | — | -$7.20M | -$3.28M | — | — |
| Net income | -$8.30M | -$7.20M | -$3.33M | -$16.50M | -$11.95M |
| EBITDA | -$2.51M | -$1.65M | -$2.40M | -$15.47M | -$11.85M |
| EPS (basic) | 2.16 | 2.43 | 1.13 | -33.52 | -1.00 |
| EPS (diluted) | 2.16 | 2.43 | 1.13 | -33.52 | -1.00 |
| Weighted avg. shares (diluted) | 3.84M | 2.96M | 2.96M | 492,066 | 11.90M |
| Balance sheet | |||||
| Cash & equivalents | $2.20M | $650,000 | $1.15M | $1.97M | $5.43M |
| Current assets | $3.18M | $780,000 | $1.82M | $9.25M | $5.72M |
| PP&E, net | $95,000 | $123,000 | $6,694 | $18,102 | $29,510 |
| Goodwill | $1.73M | — | — | — | — |
| Total assets | $11.45M | $903,000 | $1.85M | $9.28M | $5.76M |
| Current liabilities | $4.20M | $8.90M | $7.92M | $3.36M | $2.40M |
| Short-term debt | $355,000 | $7.73M | — | — | — |
| Total liabilities | $4.20M | $8.90M | $10.68M | $6.00M | $5.22M |
| Shareholders' equity | $7.25M | -$8.00M | -$1.20M | $111,000 | $542,388 |
| Shares outstanding | 4.80M | 2.96M | 810,722 | 32.43M | 16.22M |
| Cash flow statement | |||||
| Operating cash flow | -$2.77M | -$1.07M | -$3.44M | -$13.88M | -$14.94M |
| Capital expenditure | $8,000 | $6,000 | $6,000 | — | $39,560 |
| Free cash flow | -$2.77M | -$1.07M | -$3.45M | — | -$14.98M |
| Investing cash flow | $1.70M | -$6,000 | $103,000 | — | -$39,560 |
| Financing cash flow | $2.63M | $450,000 | $2.85M | $17.40M | $20.34M |
| Depreciation & amortization | $55,000 | $413,000 | $620,000 | $11,408 | $10,050 |
| Stock-based compensation | $765,000 | $208,000 | $149,000 | $22,730 | — |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.